carlisle & Associates
generic drug updates News contact carlisle medical
generic drug updates
Generic Sulfamylon® Launches
Released: 02/18/2013
By: Mike Partridge, RPh

On February 2, 2013, Par Pharmaceutical received final FDA approval for and commenced shipping the generic equivalent for Mylan’s branded product, Sulfamylon® (mafenide acetate) topical solution. Sulfamylon® had estimated total U.S. annual sales of approximately $8 million.

Sulfamylon® is indicated as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.

Company News Releases
Generic Drug Updates
Newsletter Subscription
Newsletter Login
© Copyright 2019 Carlisle Medical, Inc.
Twitter Twitter Twitter Twitter
disclaimer site map disclaimer